Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15673746rdf:typepubmed:Citationlld:pubmed
pubmed-article:15673746lifeskim:mentionsumls-concept:C0019682lld:lifeskim
pubmed-article:15673746lifeskim:mentionsumls-concept:C2349001lld:lifeskim
pubmed-article:15673746lifeskim:mentionsumls-concept:C0681850lld:lifeskim
pubmed-article:15673746lifeskim:mentionsumls-concept:C1706203lld:lifeskim
pubmed-article:15673746lifeskim:mentionsumls-concept:C2697811lld:lifeskim
pubmed-article:15673746lifeskim:mentionsumls-concept:C0031327lld:lifeskim
pubmed-article:15673746lifeskim:mentionsumls-concept:C0525005lld:lifeskim
pubmed-article:15673746lifeskim:mentionsumls-concept:C1446409lld:lifeskim
pubmed-article:15673746lifeskim:mentionsumls-concept:C0870883lld:lifeskim
pubmed-article:15673746lifeskim:mentionsumls-concept:C1550501lld:lifeskim
pubmed-article:15673746lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:15673746pubmed:issue2lld:pubmed
pubmed-article:15673746pubmed:dateCreated2005-1-27lld:pubmed
pubmed-article:15673746pubmed:abstractTextIn order to evaluate the potential risk of nelfinavir (NFV) accumulation in human immunodeficiency virus (HIV)-hepatitis C virus (HCV)-coinfected patients with liver disease, we investigated the concentrations of NFV and M8, the active metabolite of NFV, in plasma HIV-positive (HIV+) patients coinfected with HCV. A total of 119 HIV+ subjects were included in our study: 67 HIV+ patients, 32 HIV+ and HCV-positive (HCV+) patients without cirrhosis, and 20 HIV+ and HCV+ patients with cirrhosis. Most of the enrolled patients (chronically treated) were taking NFV at the standard dosage of 1,250 mg twice a day. To assay plasma NFV and M8 concentrations, patients underwent serial plasma samplings during the dosing interval at steady state. Plasma NFV and M8 concentrations were measured simultaneously by a high-performance liquid chromatography method with UV detection. The HIV+ and HCV+ patients with and without cirrhosis had significantly lower NFV oral clearances than the HIV+ and HCV-negative individuals (28 and 58% lower, respectively; P < 0.05), which translated into higher areas under the concentration-time curves for cirrhotic and noncirrhotic patients. The NFV absorption rate was significantly lower in cirrhotic patients, resulting in a longer time to the maximum concentration in serum. The mean ratios of the M8 concentration/NFV concentration were significantly lower (P < 0.05) in HIV+ and HCV+ subjects with cirrhosis (0.06 +/- 0.074) than in the subjects in the other two groups. The mean ratios for M8 and NFV were not statistically different between HIV+ and HCV-negative patients (0.16 +/- 0.13) and HIV+ and HCV+ patients without cirrhosis (0.24 +/- 0.17), but the interpatient variability was high. Our results indicate that the pharmacokinetics of NFV and M8 are altered in HIV+ and HCV+ patients, especially those with liver cirrhosis. Therefore, there may be a role for therapeutic drug monitoring in individualizing the NFV dosage in HIV-HCV-coinfected patients.lld:pubmed
pubmed-article:15673746pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15673746pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15673746pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15673746pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15673746pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15673746pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15673746pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15673746pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15673746pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15673746pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15673746pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15673746pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15673746pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15673746pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15673746pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15673746pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15673746pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15673746pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15673746pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15673746pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15673746pubmed:languageenglld:pubmed
pubmed-article:15673746pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15673746pubmed:citationSubsetIMlld:pubmed
pubmed-article:15673746pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15673746pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15673746pubmed:statusMEDLINElld:pubmed
pubmed-article:15673746pubmed:monthFeblld:pubmed
pubmed-article:15673746pubmed:issn0066-4804lld:pubmed
pubmed-article:15673746pubmed:authorpubmed-author:RegazziMarioMlld:pubmed
pubmed-article:15673746pubmed:authorpubmed-author:FabrisPaoloPlld:pubmed
pubmed-article:15673746pubmed:authorpubmed-author:MaseratiRenat...lld:pubmed
pubmed-article:15673746pubmed:authorpubmed-author:NardiniGiulia...lld:pubmed
pubmed-article:15673746pubmed:authorpubmed-author:GattiFrancesc...lld:pubmed
pubmed-article:15673746pubmed:authorpubmed-author:VillaniPaolaPlld:pubmed
pubmed-article:15673746pubmed:authorpubmed-author:CusatoMariaMlld:pubmed
pubmed-article:15673746pubmed:authorpubmed-author:ZucchiPatrizi...lld:pubmed
pubmed-article:15673746pubmed:authorpubmed-author:BrigantiElena...lld:pubmed
pubmed-article:15673746pubmed:authorpubmed-author:RodaRinaldoRlld:pubmed
pubmed-article:15673746pubmed:authorpubmed-author:SacchelliLuca...lld:pubmed
pubmed-article:15673746pubmed:authorpubmed-author:Delle...lld:pubmed
pubmed-article:15673746pubmed:authorpubmed-author:MoriFernandaFlld:pubmed
pubmed-article:15673746pubmed:authorpubmed-author:CastelliPaula...lld:pubmed
pubmed-article:15673746pubmed:authorpubmed-author:TestaLuciaLlld:pubmed
pubmed-article:15673746pubmed:issnTypePrintlld:pubmed
pubmed-article:15673746pubmed:volume49lld:pubmed
pubmed-article:15673746pubmed:ownerNLMlld:pubmed
pubmed-article:15673746pubmed:authorsCompleteYlld:pubmed
pubmed-article:15673746pubmed:pagination643-9lld:pubmed
pubmed-article:15673746pubmed:dateRevised2009-11-18lld:pubmed
pubmed-article:15673746pubmed:meshHeadingpubmed-meshheading:15673746...lld:pubmed
pubmed-article:15673746pubmed:meshHeadingpubmed-meshheading:15673746...lld:pubmed
pubmed-article:15673746pubmed:meshHeadingpubmed-meshheading:15673746...lld:pubmed
pubmed-article:15673746pubmed:meshHeadingpubmed-meshheading:15673746...lld:pubmed
pubmed-article:15673746pubmed:meshHeadingpubmed-meshheading:15673746...lld:pubmed
pubmed-article:15673746pubmed:meshHeadingpubmed-meshheading:15673746...lld:pubmed
pubmed-article:15673746pubmed:meshHeadingpubmed-meshheading:15673746...lld:pubmed
pubmed-article:15673746pubmed:meshHeadingpubmed-meshheading:15673746...lld:pubmed
pubmed-article:15673746pubmed:meshHeadingpubmed-meshheading:15673746...lld:pubmed
pubmed-article:15673746pubmed:meshHeadingpubmed-meshheading:15673746...lld:pubmed
pubmed-article:15673746pubmed:meshHeadingpubmed-meshheading:15673746...lld:pubmed
pubmed-article:15673746pubmed:meshHeadingpubmed-meshheading:15673746...lld:pubmed
pubmed-article:15673746pubmed:meshHeadingpubmed-meshheading:15673746...lld:pubmed
pubmed-article:15673746pubmed:meshHeadingpubmed-meshheading:15673746...lld:pubmed
pubmed-article:15673746pubmed:meshHeadingpubmed-meshheading:15673746...lld:pubmed
pubmed-article:15673746pubmed:meshHeadingpubmed-meshheading:15673746...lld:pubmed
pubmed-article:15673746pubmed:meshHeadingpubmed-meshheading:15673746...lld:pubmed
pubmed-article:15673746pubmed:meshHeadingpubmed-meshheading:15673746...lld:pubmed
pubmed-article:15673746pubmed:meshHeadingpubmed-meshheading:15673746...lld:pubmed
pubmed-article:15673746pubmed:year2005lld:pubmed
pubmed-article:15673746pubmed:articleTitleClinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects.lld:pubmed
pubmed-article:15673746pubmed:affiliationClinical Pharmacokinetic Unit, Department of Pharmacology, IRCCS Policlinico San Matteo, Piazzale Golgi 1, 27100 Pavia, Italy. regazzim@smatteo.pv.itlld:pubmed
pubmed-article:15673746pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15673746pubmed:publicationTypeClinical Triallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15673746lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15673746lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15673746lld:pubmed